Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response

Liver International

Volumn 37, Issue 10, 2017, Pages 1526-1534

  Bruno, Savino ^a   Di Marco, Vito ^b   Iavarone, Massimo ^c   Roffi, Luigi ^d   Boccaccio, Vincenzo ^a   Crosignani, Andrea ^d   Cabibbo, Giuseppe ^b   Rossi, Sonia ^a   Calvaruso, Vincenza ^b   Aghemo, Alessio ^c   Giacomelli, Luca ^e   Craxì, Antonio ^b   Colombo, Massimo ^c   Maisonneuve, Patrick ^f  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d ASST Nord Milano ^*  (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

hepatitis C virus; hepatocellular carcinoma; interferon; survival; sustained virological response

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; SORAFENIB; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURGERY; CAUSE OF DEATH; CHEMOEMBOLIZATION; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROPENSITY SCORE; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SUSTAINED VIROLOGIC RESPONSE; TREND STUDY; TUMOR RECURRENCE; VIREMIA; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; ITALY; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER TUMOR; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; ITALY; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85019862319     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13452     Document Type: Article

References (28)

1. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135.
2. Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? J Hepatol. 2014;61:1430-1433.
3. Bruno S, Stroffolini T, Colombo M, et al. Italian association of the study of the liver disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587.
4. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with 374 chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684.
5. EASL. European association for the study of the liver recommendations on treatment of hepatitis C. J Hepatol. 2015;63:199-236.
6. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217-1223.
7. Boccaccio V, Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int. 2014;34(Suppl 1):38-45.
8. Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int. 2015;35(Suppl 1):4-10.
9. Hsu YC, Wu CY, Lin JT. Hepatitis C virus infection, antiviral therapy, and risk of hepatocellular carcinoma. Semin Oncol. 2015;42:329-338.
10. Shirabe K, Sugimachi K, Harada N, et al. Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma. Anticancer Res. 2015;35:6963-6969.
11. Kanogawa N, Ogasawara S, Chiba T, et al. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197-1204.
12. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of viral eradication in patients with hepatitis C virus and cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151(130–39):e2.
13. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121:2874-2882.
14. van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312:1927-1928.
15. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964:50-64.
16. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35:421-430.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
18. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
19. European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.
20. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
21. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858.
22. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150-157.
23. Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147-1158.
24. Reig M, Mariño Z, Perelló C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 2016;65:719-726.
25. Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol. 2016;65:734-740.
26. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol. 2016;65:862-864.
27. Cammà C, Cabibbo G, Craxì A. Direct antiviral agents and risk for HCC early recurrence: much ado about nothing. J Hepatol. 2016;65:861-862.
28. Wang BX, Rahbar R, Fish ENJ. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res. 2011;31:545-552.